of cinacalcet include stomach upset, vomiting, diarrhea, dizziness, nausea, weakness, and chest pain. Clinical trials conducted in the United States by Amgen to determine whether the drug is safe in children were halted by the U.S. Food and Drug Administration (FDA) in February 2013, following the death of a 14-year-old participant. Overdose Serious side effects, including overdose symptoms, of cinacalcet include: burning tingling unusual feelings of the lips, tongue, fingers, or feet muscle aches or cramps sudden tightening of muscles in hands, feet, face, or throat seizures Interactions Cinacalcet is a strong inhibitor of the liver enzyme CYP2D6 and is partially metabolized by CYP3A4 and CYP1A2. Dose adjustments may be necessary if people are treated with CYP3A4 and CYP1A2 inhibitors and medications that are metabolized by CYP2D6. Pharmacology Mechanism of action Cinacalcet is a drug that acts as a calcimimetic (i.e. it mimics the action of calcium on tissues) by allosteric activation of the calcium-sensing receptor that is expressed in various human organ tissues. The calcium-sensing receptors on the surface of the chief cell of the parathyroid gland is the principal negative regulator of parathyroid hormone secretion. Cinacalcet increases the sensitivity of calcium receptors on parathyroid cells to reduce parathyroid hormone (PTH) levels and thus decrease serum calcium levels. References External links CYP2D6 inhibitors Nephrology procedures Systemic hormonal preparations Trifluoromethyl compounds 1-Naphthyl compounds